Citi raised the firm’s price target on Neurocrine to $150 from $140 and keeps a Neutral rating on the shares post the Q1 report. The firm added the company’s two mid-stage neuropsychiatry assets to its valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $160 from $150 at H.C. Wainwright
- Neurocrine management to meet with Oppenheimer
- Neurocrine backs FY24 INGREZZA net product sales view $2.1B-$2.2B
- Neurocrine reports Q1 adjusted EPS $1.20, consensus $1.01
- Neurocrine Biosciences Reports First Quarter 2024 Financial Results